Skip to content

Meet us at COP31Read more

AEON Biopharma Inc Sustainability Reports

A clinical-stage biopharmaceutical company focused on developing its proprietary botulinum toxin complex, ABP-450, for the treatment of multiple debilitating medical conditions.

Sector: Manufacturing

Country: United States

Exchange: NYSE American

6 reports from 2020 to 2025